Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 4/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | THPO | P40225 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23686109 | 0.90 | HTT (0.49) | HTTNPSR1HPGDSMN1; SMN2KDM4E | |
| SCHEMBL9123042 | 0.90 | HSP90AA1 (0.57) | HTTNPSR1HPGDSMN1; SMN2HSP90AA1 | |
| SCHEMBL9213691 | 0.90 | PYGM (0.50) | HTTNPSR1HPGDSMN1; SMN2HSP90AA1 | |
| SCHEMBL9119166 | 0.89 | TSHR (0.51) | HTTNPSR1HPGDSMN1; SMN2HSP90AA1 | |
| SCHEMBL9222512 | 0.88 | HTT (0.47) | HTTNPSR1HPGDSMN1; SMN2KDM4E | |
| SCHEMBL9217138 | 0.88 | HTT (0.51) | HTTNPSR1HPGDSMN1; SMN2KDM4E | |
| SCHEMBL9121005 | 0.88 | KDM4E (0.45) | HTTHSP90AA1HSP90AB1KDM4EGAA | |
| SCHEMBL23686215 | 0.88 | HTT (0.53) | HTTNPSR1HPGDSMN1; SMN2KDM4E | |
| SCHEMBL21001936 | 0.87 | LMNA (0.58) | HPGDSMN1; SMN2KDM4EGAATSHR | |
| SCHEMBL9122440 | 0.87 | TSHR (0.60) | HTTNPSR1HPGDSMN1; SMN2HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0451654-B1 | Use of N-alkylated 1,4-dihydropyridine carboxylic acid esters as drugs, new compounds and process for their preparation | BAYER AG (DE) | 1994-09-07 | — | — | EP | claimed |
| US-5234935-A | Preventing myocardial infarct | BAYER AKTIENGESELLSCHAFT (DE) | 1993-08-10 | — | — | US | claimed |
| US-20210230117-A1 | DIHYDROPYRIDINES FOR THE TREATMENT OF COGNITIVE IMPAIRMENT OR TRAUMATIC BRAIN INJURY | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2021-07-29 | — | — | US | disclosed |
| US-5432185-A | Treating patients exhibiting acute or chronic ischaemic disorders associated with disorders of microcirculation, without lowering or increasing blood pressure | BAYER AKTIENGESELLSCHAFT (DE) | 1995-07-11 | — | — | US | disclosed |
| US-5234935-A | Preventing myocardial infarct | BAYER AKTIENGESELLSCHAFT (DE) | 1993-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210230117-A1 | DIHYDROPYRIDINES FOR THE TREATMENT OF COGNITIVE IMPAIRMENT OR TRAUMATIC BRAIN INJURY | GAP43, SYNJ1, PSD | HTT 1468/4885NPSR1 1601/4885HPGD 1858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.